Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SLGL
Upturn stock ratingUpturn stock rating

Sol Gel Technologies Ltd (SLGL)

Upturn stock ratingUpturn stock rating
$1.26
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: SLGL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -74.37%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 35.10M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 984462
Beta 1.6
52 Weeks Range 0.33 - 1.65
Updated Date 01/14/2025
52 Weeks Range 0.33 - 1.65
Updated Date 01/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.34

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -227.4%
Operating Margin (TTM) 29.89%

Management Effectiveness

Return on Assets (TTM) -21.63%
Return on Equity (TTM) -35.85%

Valuation

Trailing PE -
Forward PE 9.34
Enterprise Value 7519872
Price to Sales(TTM) 5.35
Enterprise Value 7519872
Price to Sales(TTM) 5.35
Enterprise Value to Revenue 0.64
Enterprise Value to EBITDA 0.24
Shares Outstanding 27857600
Shares Floating 7671153
Shares Outstanding 27857600
Shares Floating 7671153
Percent Insiders 65.17
Percent Institutions 19.36

AI Summary

Sol Gel Technologies Ltd. (SLGL) - A Comprehensive Overview

Company Profile:

Detailed History and Background:

Sol Gel Technologies Ltd. (SLGL) is a publicly traded, development-stage company focused on the research, development, and commercialization of inorganic-organic hybrid materials. Founded in 1990 and headquartered in Israel, SLGL has been exploring the potential of sol-gel technology for diverse applications across various industries.

Core Business Areas:

SLGL's core business areas primarily revolve around three main applications of its sol-gel technology:

  • Electronics: SLGL develops and licenses sol-gel solutions for high-performance electronics, including dielectric, encapsulation, and passivation materials.
  • Clean Technology: SLGL explores applications of its technology in areas like water purification, environmental remediation, and energy storage.
  • Life Sciences: SLGL investigates the use of sol-gel materials in drug delivery, diagnostic tools, and wound healing applications.

Leadership Team and Corporate Structure:

The current leadership team of SLGL includes:

  • Dr. Efrat Ben-Yosef: Chief Executive Officer
  • Dr. Ronen Barkan: Chief Technology Officer
  • Mr. Uri Ashkenasi: Chief Financial Officer

The company operates with a lean structure, focusing on research and development rather than direct manufacturing. They collaborate with partners for manufacturing and commercialization of their technologies.

Top Products and Market Share:

Top Products and Offerings:

SLGL's top products and offerings include:

  • Silane-based materials: These materials find applications in the electronics industry as dielectric and encapsulation layers in electronic devices.
  • Titania-based materials: These materials hold potential for use in water purification and environmental remediation processes.
  • Biocompatible materials: SLGL develops biocompatible materials for applications in drug delivery and wound healing.

Market Share Analysis:

Estimating SLGL's market share is challenging due to its diverse product portfolio and applications. In the electronics industry, where its silane-based materials find use, SLGL faces competition from established players like Cabot Corporation and Wacker Chemie. In the clean technology and life sciences sectors, the company operates in niche markets with specific applications.

Product Performance and Market Reception:

SLGL's products have received positive attention, particularly in the electronics industry for their potential to enhance device performance and reliability. However, the company hasn't generated significant revenue yet as it focuses on research and development.

Total Addressable Market:

SLGL operates in diverse markets with significant potential. The global market for electronic materials is estimated to be over $400 billion, while the clean technology and life sciences markets are valued at over $1 trillion and $1.5 trillion respectively. This signifies a massive addressable market for SLGL's technology.

Financial Performance:

Recent Financial Statements Analysis:

SLGL is a development-stage company and does not currently generate significant revenue. Its primary expenses lie in research and development activities. The company has incurred net losses in recent years, but these are attributed to its pre-revenue stage.

Year-over-Year Performance:

SLGL's recent financial performance reflects its development stage. Revenue remains negligible, and net losses continue as the company invests in research and development.

Cash Flow and Balance Sheet Health:

SLGL primarily relies on funding from investors and research grants. The company maintains a relatively healthy cash position due to its low operating expenses.

Dividends and Shareholder Returns:

Dividend History:

SLGL has not paid any dividends to date, considering its pre-revenue stage and focus on reinvesting resources for growth.

Shareholder Returns:

Shareholder returns have been volatile due to the company's development stage and lack of revenue generation.

Growth Trajectory:

Historical Growth Analysis:

SLGL's historical growth has been primarily focused on research and development rather than revenue generation.

Future Growth Projections:

SLGL's future growth will depend on its success in commercializing its technologies and generating revenue. Recent advancements in its silane-based materials for electronics and ongoing research in clean technology and life sciences show positive potential.

Recent Product Launches and Strategic Initiatives:

SLGL recently entered into a collaboration with a major electronics manufacturer to develop and supply next-generation dielectric materials. This indicates a significant step towards commercialization and future growth.

Market Dynamics:

Industry Overview:

The inorganic-organic hybrid materials market is expected to witness significant growth in the coming years, driven by advancements in electronics, clean technology, and life sciences. However, intense competition exists within each application segment.

SLGL's Positioning:

SLGL positions itself as an innovative player in the sol-gel technology space, focusing on developing tailored solutions for specific customer needs. Its collaborations with established players in various industries indicate its potential to gain market share.

Competitors:

Key Competitors:

  • Cabot Corporation (CBT)
  • Wacker Chemie (WCH)
  • Evonik Industries (EVK)
  • BASF (BAS)

Market Share Comparison:

Estimating precise market share percentages for SLGL is challenging due to its diverse applications and pre-revenue stage. However, the company faces competition from established players in each of its target markets.

Competitive Advantages and Disadvantages:

SLGL's competitive advantages lie in its proprietary sol-gel technology and its focus on developing customized solutions for specific applications. However, its pre-revenue stage and lack of proven commercial success are disadvantages compared to established players.

Potential Challenges and Opportunities:

Key Challenges:

SLGL faces challenges in scaling up its technology, navigating intense competition, and securing continued funding for research and development.

Potential Opportunities:

SLGL has opportunities to expand its market reach through strategic partnerships, successfully commercialize its technologies, and generate revenue through licensing agreements or direct sales.

Recent Acquisitions:

SLGL has not engaged in any acquisitions in the past three years.

AI-Based Fundamental Rating:

Rating: 5/10

Justification:

SLGL's rating reflects its potential and innovative technologies. However, its pre-revenue stage, lack of proven commercial success, and intense competition present significant challenges. The company's ability to overcome these obstacles and generate revenue will determine its future success.

Sources and Disclaimers:

Sources:

Disclaimer:

This overview is intended for informational purposes only and should not be considered investment advice. Before making any investment decisions, conduct thorough research and consult with a financial professional.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters -
IPO Launch date 2018-01-23
Co-Founder, CEO & Director Dr. Alon Seri-Levy
Sector Healthcare
Industry Biotechnology
Full time employees 36
Full time employees 36

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​